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Heart failureIn pathological conditions, the balance between reactive oxygen species (ROS) and antioxidants may shift
toward a relative increase of ROS, resulting in oxidative stress. Conﬂicting data are available on antioxidant
defenses in human failing heart and they are limited to the left ventricle. Thus, we aimed to investigate and
compare the source of oxidant and antioxidant enzyme activities in the right (RV) and left (LV) ventricles of
human failing hearts. We found a signiﬁcant increase in superoxide production only by NADPH oxidase in
both failing ventricles, more marked in RV. Despite unchanged mRNA or protein expression, catalase (CAT)
and glutathione peroxidase (GPx) activities were increased, and their increases reﬂected the levels of Tyr
phosphorylation of the respective enzyme. Manganese superoxide dismutase (Mn-SOD) activity appeared
unchanged. The increase in NADPH oxidase-dependent superoxide production positively correlated with the
activation of both CAT and GPx. However, the slope of the linear correlation (m) was steeper in LV than in RV
for GPx (LV: m=2.416; RV: m=1.485) and CAT (LV: m=1.007; RV: m=0.354). Accordingly,
malondialdehyde levels, an indirect index of oxidative stress, were signiﬁcantly higher in the RV than LV.
We conclude that in human failing RV and LV, oxidative stress is associated with activation of antioxidant
enzyme activity. This activation is likely due to post-translational modiﬁcations and more evident in LV.
Overall, these ﬁndings suggest a reduced protection of RV against oxidative stress and its potential
contribution to the progression toward overt heart failure.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Myocardial oxidative stress due to increased generation of reactive
oxygen species (ROS) plays a recognized role in the pathogenesis as
well as the progression of heart failure (HF) [1–4]. The myocardium is
equipped with a variety of endogenous enzymatic and non-enzymatic
antioxidant systems that are sufﬁcient tometabolize ROS. In particular,
superoxide dismutase (SOD), glutathione peroxidase (GPx) and
catalase (CAT) counteract the cytotoxic effects of reactive oxygen
metabolites [5]. In HF, an imbalance between ROS production and
cellular antioxidant defenses might inﬂuence myocardial function
deterioration and disease progression [6]. Potential sources of
increased ROS generation in failing heart include the mitochondria
and enzymes, such as xanthine oxidase, cytochrome P450 oxidases,
uncoupled NO synthases and NADPH oxidases. Recent studies,
including ours, have demonstrated that NADPH oxidase was the
major source of ROS in the human failing myocardium and that it was
important in the pathogenesis of several aspects of cardiac remodeling39 554598905.
ll rights reserved.largely through actions on redox-sensitive signal transduction [7–10].
To date, a comprehensive view of changes in oxidative stress
mechanisms and antioxidant enzyme activity in human HF is far to
be completely understood. Moreover, the currently available infor-
mation is somehow contradictory. For example, CAT activity in the
failing human ventricle was reported to be either decreased [11],
upregulated [5] or unchanged [12] in different studies. The same
studies showed either no change inmRNA, protein levels, SODandGPx
activity [5,6,11] or decreased Mn-SOD activity though in the presence
of upregulated mRNA levels [12]. Altogether, they highlight the need
to evaluate the oxidative and antioxidant environment in a compre-
hensive manner and, if possible, to compare alterations occurring in
different compartments of the same heart.
In patients with advanced HF, attention has long been attracted by
the functional assessment of the left ventricle (LV) with little – if any –
interest toward the right one (RV) [13]. Recently, the importance of
RV function as a powerful predictor of mortality in HF has been
acknowledged [14,15], but little is known about the concomitant
cellular and molecular changes occurring in the RV associated with
HF. Indeed, only some recent studies inferred that unlike mechanisms
account for cardiac hypertrophy and failure in RV and LV [16–18].
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use of left ventricular assist device (LVAD) as a bridge to heart
transplantation or as destination therapy in end-stage HF patients
[19]. In fact, despite the general clinical beneﬁt of LVAD [20,21], RV
failure after device implantation emerged as a major post-operative
problem and is associated with a high mortality rate [22].
In our previous study [10], we demonstrated that oxidative stress
resulting from increased ROS generation by NADPH oxidase was
present in both ventricles of end-stage human failing heart, but more
marked in failing RV. Based on these ﬁndings, the present study was
aimed at investigating whether the increase in ROS generation in the
failing human ventricles was accompanied by changes in antioxidant
enzyme expression and/or activity with respect to non-failing (NF)
hearts, and to assess whether these changes were equally coordinated
in the LV and RV.
2. Materials and methods
2.1. Source of tissue
All patients gave their informed consent prior to their inclusion in
the study that conformed to the Declaration of Helsinki and
institutional ethical regulations. Explanted failing hearts were
obtained from patients undergoing transplantation for end-stage
heart failure secondary to idiopathic dilated cardiomyopathy (n=4
male, n=1 female;mean age 39 years, range 30–60) or ischemic heart
disease (n=6 male, n=1 female; mean age 60 years, range 53–69).
All patients were in New York Heart Association class III/IV, with a
mean LV ejection fraction of 22% and a mean pulmonary artery
pressure of 33 mm Hg. Non-failing (NF) donor hearts (n=4 male,
n=3 female; no cardiacmedication;mean age 45 years, range40–50;)
which were unsuitable for transplantation for technical reasons, were
used as controls. Clinical characteristics of the three groups are shown
in Table 1.
Immediately after explant, myocardial tissue samples were snap-
frozen in liquid nitrogen-chilled isopentane for protein, RNA analysis
and biochemistry. All tissues were stored at −80 °C. Prior to each
experiment, sections stained with hematoxylin–eosin and Masson
Trichrome stain was obtained from each sample for morphological
examination. Histologic slides from both failing and non-failing hearts
were observed under light microscopy.Table 1
Clinical characteristics of the patients.
NF IHD DCM
Total number 7 7 5
Sex (M/F) 4/3 6/1 4/1
Age (range) 45 (40–50) 39 (30–60) 60 (53–69)
LVEF (%) 23±4.8 20±2.5
CI (l/min/m2) 2,4±0.2 1.8±0.05
PAP (mm Hg) 38±3.2 29±5.4
PCWP (mm Hg) 24±3 21±5.4
RAP (mm Hg) 15±4.2 10.5±2.3
NYHA class III–IV III–IV
Medication
Diuretics 7 5
Digoxin 0 1
Antiarrhythmics 2 1
ACE-I 7 5
β-blockers 7 5
Nitrates 4 0
HMGCoA-Inh 2 0
ANF/rRNA 18S 1.03±0.001 12.4±1.05 12.3±0.98
MCH-α/rRNA 18S 1.30±0.03 0.06±0.01 0.04±0.002
MCH-β/rRNA 18S 1.35±0.2 0.06±0.02 0.54±0.05
LVEF, left ventricular ejection fraction; CI , cardiac index; ACE-I, angiotensin converting
enzyme inhibitors; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge
pressure; RAP, right atrial pressure; HMGCoA inhibitors (statins); ANF, atrial natriuretic
factor; MHC, myosin heavy chain.Myocyte hypertrophy was a common ﬁnding in all failing hearts,
associated with variable degrees of interstitial ﬁbrosis, graded from
mild (+ 1) to severe (+ 3) on a semi-quantitative basis (not shown).
According to the results of the histologic examination, myocardial
sampleswithminimal amounts of ﬁbrosis and devoid of inﬂammatory
inﬁltrates were selected for molecular and biochemical studies. In
addition, expression of atrial natriuretic factor (ANF), and myosin
heavy chain (MHC)-α and -β isoforms, molecular markers of cardiac
hypertrophy, were evaluated both on NF and failing hearts by RT-PCR
using the Platinum SYBR Green qPCR Super Mix- UDG (Invitrogen,
Italy) [23].
2.2. Sample preparation
LV and RV samples from NF and failing hearts were homogenized
in ice-cold 20 mM Tris–HCl pH 7.4, containing 10 μg/ml leupeptin,
10 μg/ml aprotinin, 0.2 mM PMSF and phosphatase inhibitor cocktail
(Sigma, Italy). After spinning for 10 min at 3000 rpm at 4 °C on an
Eppendorf Centrifuge 5804 R (Eppendorf, Italy), samples of total heart
homogenates were used for NADPH oxidase activity, Western
blotting, lipid peroxidation assay and antioxidant enzyme activities.
Protein concentration was measured by bicinchoninic acid (BCA)
protein assay (Pierce, Italy).
2.3. NADPH oxidase activity
Superoxide production by NADPH oxidase was assessed in tissue
homogenates from NF and failing hearts using lucigenin (5 μM)-
enhanced chemiluminescence (300 μM NADPH; 100 μg protein /
tube), as previously described [10]. Furthermeasurements were taken
after the addition of speciﬁc inhibitors of oxidase systems: dipheny-
leneiodonium (DPI, 20 μM), a NADPH oxidase ﬂavoprotein inhibitor,
Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME, 100 μM), a
nitric oxide synthase inhibitor; rotenone (50 μM), a mitochondrial
oxidase complex I inhibitor; oxypurinol (100 μM), a xanthine oxidase
inhibitor. A cell-permeable superoxide scavenger 4,5-dihydroxy-1,3-
benzene-disulfonic acid (Tiron, 20 mM) was also used. A buffer blank
was subtracted from each reading. Superoxide production was
expressed as an arbitrary light unit over 10 min.
2.4. Nox4 gene expression
Total RNA from each cardiac sample was isolated and DNase-
treated with the RNeasy Fibrous Tissue Mini Kit (Qiagen, Italy)
following the manufacturer's instructions. Isolated RNA was quanti-
ﬁed (spectrophotometric absorbance at 260 nm) and its purity was
conﬁrmed by the A260/A280 ratio. The integrity of total RNA was
evaluated by ethidium bromide staining on a denaturing agarose gels.
RNA samples were stored at −80 °C. Single-stranded cDNA was
obtained by using High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, CA, USA) following manufacturer's instructions.
Reverse transcription was performed at 25 °C for 10 min and 37 °C for
120min and stopped by incubating at 85 °C for 5 s. Expression levels of
Nox4 gene were investigated using real-time quantitative RT-PCR and
TaqMan® probe-based chemistry. Primers and probes for Nox were
obtained from ABI (Foster City, CA, USA) TaqMan Gene Expression
Assay catalogue. These assays come in a 20× reaction mix, span an
exon–exon junction and are optimized to give approximately 100%
efﬁciency. GAPDH was used as a housekeeping gene [Human GAPD
(GAPDH) Endogenous Control (VIC / MGB Probe, Primer Limited)
Applied BioSystems, CA, USA]. The real-time RT-PCR reactions were
carried out using TaqMan® Gene Expression Master Mix (Applied
BioSystems, CA, USA) in a 20 μl reaction volume containing 50 ng of
cDNA. All reactions were performed in triplicate and included a
negative control. PCR reactions were carried out using an ABI Prism
7500 Sequence Detection System (Applied Biosystems, CA, USA).
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15 s at 95 °C and 1 min at 60 °C. The relative quantiﬁcation of mRNA
levels was obtained by the 7500 system software which uses the
comparative method (ΔCT).
2.5. Mn-SOD, GPx and CAT gene expression
Relative expression of Mn-SOD, GPx and CAT genes was deter-
mined by quantitative RT-PCR using the Platinum SYBR Green qPCR
Super Mix- UDG (Invitrogen, Life Technologies, Paisley, UK). PCR
conditions and primers for Mn-SOD and GPx were as previously
detailed [23]; for CAT gene expression, we used the following set of
primers: forward primer GCAGGACAATCAGGGTGGTG; reverse primer
GGAGAAGTGCGGAGATTCAACA. Quantitative RT-PCR was performed
in triplicate using 1 μl of cDNA template in a 50 μl reaction. The
linearity and efﬁciency of PCR ampliﬁcations were assessed using
standard curves generated by serial dilution of cDNA; in addition, melt
curve analysis was used to conﬁrm the speciﬁcity of ampliﬁcation and
absence of primer dimers. In all samples, the relative expression of
each target gene respect to the control (reference sample) was
evaluated by the comparative threshold cycle (ΔCt) method. All
values were normalized to the 18S rRNA housekeeping gene.
2.6. Mn-SOD, GPx and CAT protein expression
The expression of the antioxidant enzymes was evaluated by
Western blotting. Equal amounts (35 μg/sample) of tissue homo-
genates were separated on 12% SDS-PAGE, transferred to polyvinyli-
dine diﬂuoride (PVDF) membranes (Millipore, MA, USA) and
immunoblotted with either polyclonal anti-SOD2 (1:1000, sc-30080),
polyclonal anti-GPx (1:1000, sc-30147) or polyclonal anti-CAT
(1:1000, sc-34282) (Santa Cruz Biotech, Santa Cruz, CA, USA) and
subsequently with anti-rabbit (1:20,000 for SOD2 or 1:10000 for GPx,
sc-2004) or -goat (1:3000 for CAT, sc-2033) horseradish peroxidase-
conjugated antibodies (Santa Cruz Biotech, Santa Cruz, CA, USA). The
immunoreactive bands were detected by chemiluminescence Immo-
bilion Western ERP Substrate (Millipore, MA, USA) and quantiﬁed by
densitometric analysis using a Gel Logic 2200 Imaging System and a
Kodak Molecular Imaging Software (Kodak, CT, USA). GAPDH (1:5000,
sc-25778, Santa Cruz Biotech, Santa Cruz, CA, USA) was used as a
reference for equal protein loading.Fig. 1.NADPH-dependent superoxide production in human RV (open bars) and LV (solid bars
(A). Data are presented as mean±SEM and expressed as fold increase calculated by normal
failing (F) ventricles from hearts with IHD or DCM; ⁎⁎⁎pb0.001 vs. NF; †††pb0.001 vs. failing
dependent superoxide production in RV and LV from human failing hearts. Data are presente
inhibitors (NoI); ⁎⁎⁎pb0.001 vs. NoI.2.7. Assessment of CAT and GPx phosphorylation
To assess CAT and GPx phosphorylation, the same membrane used
for evaluating protein expression was stripped and reprobed with
mouse monoclonal anti-phosphotyrosine (p-Tyr) antibody (1:1000,
sc-7020, SantaCruzBiotechnology, SantaCruz, CA,USA) andanti-mouse
(1:5000, sc-2005) horseradish peroxidase-conjugated secondary anti-
body (Santa Cruz Biotechnology, Santa Cruz, , CA, USA).
2.8. Antioxidant enzyme activities
2.8.1. CAT activity assay
Seventy micrograms of tissue homogenates was added to 100 mM
phosphate buffer, pH 6.8, containing 10 mM H2O2. CAT activity
was determined by the procedure of Aebi [24], following the
decrease in absorbance at 240 nm of H2O2 for 30 s at 25 °C. The
activity was calculated using a H2O2 extinction coefﬁcient of 43.6×
103 M−1×cm−1.and was expressed as μmol/min/mg of protein.
2.8.2. GPx activity assay
Seventy micrograms of tissue homogenate was added to 100 mM
phosphate buffer, pH 7.4, containing 0.5 mM EDTA, 1.0 mM NaN3,
0.25 mMNADPH, 2.25 mMGSH, 1.0 U/ml glutathione reductase. After
addition of 0.24 mM tert-butil hydroperoxide (Sigma, Italy), the
change in optical density of NADPH was monitored spectrophoto-
metrically at 340 nm for 2.0 min at 25 °C [23]. GPx activity was
calculated using amolar extinction coefﬁcient for NADPH of 6.22×103
M−1×cm−1 and expressed as nmol/min/mg protein.
2.8.3. Mn-SOD activity assay
Mn-SODactivitywas evaluated in 10 μg of tissue homogenate using
a Chemical Superoxide Dismutase Assay kit (Cayman Chemical, Ann
Arbor, MI, USA) as previously described [23] and expressed as U/mg
protein.
2.9. Lipid peroxidation
Oxidative stress was detected by measuring malondialdehyde
(MDA) concentration, as a marker of lipid peroxidation. A Bioxytech
LPO-586 (Oxis International Inc, Prodotti Gianni, Italy) was used to
this purpose.) from non-failing (NF) and failing (F) hearts detected by lucigenin chemiluminescence.
izing values obtained in failing ventricles to average data from NF; n=7 NF and n=12
RV. MLU, mean arbitrary light units. (B) Effect of speciﬁc oxidases inhibitors on NADPH-
d as mean±SEM and expressed as percentage of the value measured in the absence of
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All values are expressed as mean±SEM. Student's t-test was used
for statistical analysis of the data. Correlation was obtained using a
linear (Pearson) correlation test. Probabilities of pb0.05 were
considered statistically signiﬁcant.
3. Results
The results of all experiments did not differ according to the
etiology of heart disease. Thus, in the following sections, the study
population is grouped in failing and non-failing hearts.
3.1. Increased NADPH oxidase in failing right and left ventricles
In our previous work [10], we provide evidence that NADPH
oxidasewas themajor source of ROS in humanend-stagemyocardium.
In the present study, we conﬁrmed a signiﬁcant increase in NADPH-
dependent superoxide production activity in both failing ventricles
(RV: 291.7±12.7 MLU/sec/mg; LV: 359.0±18.0 MLU/sec/mg;) as
compared with NF controls ( RV: 132.8±16.6 MLU/sec/mg; LV:
227.1±10.1 MLU/sec/mg; pb0.001, F vs. NF). Notably, this increase
was signiﬁcantly higher in the failing RV (2.20-fold) than in the LV
(1.58-fold) (pb0.001) (Fig. 1A). Moreover, NADPH-dependent
superoxide production was greatly reduced in both failing ventricles
only in the presence of the NADPH oxidase inhibitor diphenyleneio-
donium (DPI) and of the O2− scavenger Tiron, whereas it was
unaffected by the xanthine oxidase inhibitor oxypurinol, by a NOS
inhibitor (L-NAME), or by the inhibitor of the mitochondrial electron
transport chain, rotenone, supporting the main superoxide produc-
tion attributable to NADPH oxidase activity (Fig. 1B).
3.2. Nox4 mRNA in failing right and left ventricles
To elucidate the mechanisms underlying the increased NADPH
oxidase (Nox) activity in failing hearts, in a recent workwe focused on
Nox2, a catalytic subunit responsible for activity of the oxidase in
cardiac cells, and its regulatory subunit p47phox. To address the
question whether different NADPH oxidase isoforms may account for
regional (i.e., RV vs. LV) differences in ROS production, in this study
we analyzed the expression of the other cardiac isoform of NADPH
oxidase, Nox4. No signiﬁcant differences emerged between RV and LV
samples. In fact, Nox4 mRNA (Fig. 2) was unchanged in both failing
ventricles as compared to NF. These results strengthen the ﬁndingsFig. 2. Nox4 gene expression in human RV (open bars) and LV (solid bars) from non-
failing (NF) and failing (F) hearts evaluated by real-time quantitative RT-PCR. Data are
presented as mean±SEM and expressed as fold increase relative to NF (NF=1); n=7
NF and n=12 failing ventricles from hearts with IHD or DCM.previously reported [10] that increased oxidative stress due to NADPH
oxidase is mainly attributable to post-transcriptional mechanisms.
3.3. Antioxidant enzymatic defenses
Wemeasured the mRNA and protein levels as well as the activities
of H2O2 scavenging enzymes CAT, GPx and Mn-SOD. As shown in Fig.
3, CAT mRNA (Fig. 3A) and protein levels (Fig. 3B), assessed byFig. 3. Catalase (CAT) gene expression, protein expression and catalytic activity in
human RV (open bars) and LV (solid bars) from non-failing (NF) and failing (F) hearts.
CAT gene expression was evaluated by real-time quantitative RT-PCR (A). Represen-
tative immunoblot (upper) and densitometric quantiﬁcation (lower) of ratio of CAT to
GAPDH protein expression (B). CAT enzymatic activity (C). Data are presented as
mean±SEM and expressed as fold increase relative to NF (NF=1). n=7 NF and
n=12 failing heart ventricles from hearts with IHD or DCM. ⁎pb0.05 vs. NF;
⁎⁎⁎pb0.001 vs. NF; †pb0.05 failing LV vs. failing RV.
Fig. 4. Glutathione peroxidase (GPx) gene expression, protein expression and catalytic
activity in human RV (open bars) and LV (solid bars) from non-failing (NF) and failing
(F) hearts. GPx gene expression was evaluated by real time quantitative RT-PCR (A).
Representative immunoblot (upper) and densitometric quantiﬁcation (lower) of ratio
of GPx to GAPDH protein expression (B). GPx enzymatic activity (C). Data are presented
as mean±SEM and expressed as fold increase relative to NF (NF=1); n=7 NF and
n=12 failing ventricles from hearts with IHD or DCM; ⁎⁎pb0.01 vs. NF.
Fig. 5. Mn-Superoxide Dismutase (Mn-SOD) gene expression, protein expression and
catalytic activity in human RV (open bars) and LV (solid bars) from non-failing (NF)
and failing (F) hearts. Mn-SOD gene expression was evaluated by real-time quantitative
RT-PCR (A). Representative immunoblot (upper) and densitometric quantiﬁcation
(lower) of ratio of Mn-SOD to GAPDH protein expression (B). Mn-SOD enzymatic
activity (C). Data are presented as mean±SEM and are expressed as fold increase
relative to NF (NF=1); n=7 NF and n=12 failing ventricles from hearts with IHD or
DCM; ⁎⁎⁎pb0.001 vs. NF.
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failing RV and LV. In contrast, the enzymatic activity of CAT was
signiﬁcantly elevated in both ventricles from failing hearts. Such an
increase was more evident in the LV (LV 3.04-fold pb0.001; RV 1.76-
fold, pb0.05; F vs. NF) (Fig. 3C). In addition, in failing hearts the
absolute levels of CAT activity in the LV (23.88±1.50 μmol/min/mg
protein) were signiﬁcantly higher than in the RV (17.13±1.29 μmol/
min/mg protein) (pb0.05; LV vs. RV).Similar to CAT, GPx levels were stable in terms of mRNA levels
(Fig. 4A) and protein content. The 23 kDa band from failing RV and
LV samples, representing the GPx monomer [11], appeared un-
changed with respect to NF, as conﬁrmed by densitometric analysis
(Fig. 4B). Instead, a signiﬁcant and parallel increase of GPx activitywas
observed in failing RV and LV with respect to NF hearts (RV 1.52-fold,
pb0.01; LV 1.65-fold, pb0.01; F vs. NF) (Fig. 4C).
Fig. 7. Correlations betweenNADPH-dependent superoxide production (x axis) andGPx
(A) or CAT (B) enzymatic activity (y axis) of NF and failing hearts; n=5 NF and n=8
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NF RV) but not in the failing LV (Fig. 5A), whereas Mn-SOD protein
expression (Fig. 5B) and its enzymatic activity were unchanged in
both failing ventricles (Fig. 5C).
Overall, these ﬁndings suggest that a consistent, similar adaptive
response does occur in human failing LV and RV, as far as the
enzymatic activity is concerned. This increase in antioxidant enzyme
activities, more evident in failing LV (in particular for CAT), seems to
be largely attributable to post-translational modiﬁcations likely
induced by oxidative stress.
3.4. Tyrosine (Tyr) phosphorylation in failing RV and LV
Recently, oxidative stress has been shown to activate the Abl family
of mammalian non-receptor tyrosine kinases resulting in increased
CAT and GPx phosphorylation and activity [25]. To determine whether
the observed increases in CAT and GPx activity in our failing samples
could be attributed to Tyr phosphorylation, the same membrane used
to analyze CAT and GPx protein expression was subsequently blotted
with an anti-phospho-Tyr antibody. Interestingly, for both enzymes the
bands corresponding to failing RV and LV showed a signiﬁcant
increases in Tyr phosphorylation with respect to NF ones. Moreover,
the increase in CAT phosphorylation was signiﬁcantly (pb0.05) higher
in LV than RV, whereas no difference was observed between the two
ventricles inGPxphosphorylation (Fig. 6), thus suggesting that changes
in Tyr phosphorylation and enzyme activities go hand-in-hand.
3.5. Correlation between NADPH oxidase and antioxidant
enzyme activities
In order to verify a possible link between oxidative stress and
antioxidant enzyme activation, we correlated the activity of NADPH
oxidase with that of GPx and CAT in the RV and LV. As shown in
Fig. 6, a signiﬁcantly positive correlation was found between the
values of the GPx (RV: r=0.6897, p=0.0091; LV: r=0.8744,
p=0.0001) (Fig. 7A) and CAT (RV: r=0.8142, pb0.0007; LV:
r=0.7784, pb0.0001) (Fig. 7B) and that of NADPH oxidase in the
LV and RV. Interestingly, the slope of the linear correlation (m)
appeared to be steeper in the LV than in RV for both GPx (LV:
m=2.416; RV: m=1.485) and CAT (LV: m=1.007; RV: m=0.354),
suggesting that the oxidative stress promotes antioxidant adaptive
responses more intensively in LV versus RV.Fig. 6. CAT andGPx tyrosine (Tyr) phosphorylation in human RV and LV fromnon-failing
(NF) and failing (F). Representative immunoblot (upper) and densitometric quantiﬁca-
tion related to GAPDH expression, shown, respectively, in Fig. 3 for CAT and in Fig. 4 for
GPx, (lower) of phosphorylation expressed as fold increase of F relative to NF (NF=1)
ventricles. n=5 NF and n=5 failing ventricles from hearts with IHD or DCM.
failing ventricles from hearts with IHD and DCM. NADPH-dependent superoxide
production is expressed as MLU/s/mg protein (MLU, Mean Light Unit). GPx activity is
expressed as nmol/min/mg protein. CAT activity is expressed as μmol/min/mg protein.3.6. Lipid peroxidation
Consistent with the differences observed in antioxidant enzymes
activities, theMDA levels, measured as an indirect marker of oxidative
stress, were signiﬁcantly increased in both ventricles from failing
hearts. However, diseased RV exhibited a marked rise in lipoperoxi-
dative damage as compared to the NF control (RV: 1.95-fold; LV: 1.64-
fold); in addition, the latter resulted signiﬁcantly higher than that of
diseased LV.
4. Discussion
In this study, we reported that, in human failing hearts, the
increased ROS generation by NADPH oxidase is associated with
enhanced activity of two antioxidant enzymes. This adaptive response
mainly occurs through a post-translational modiﬁcation and appears
moremarked in the LV. NADPH oxidase activity and lipid peroxidation
are higher in RV than LV. Thus, RV might be less protected against
oxidative stress damage.
337E. Borchi et al. / Biochimica et Biophysica Acta 1802 (2010) 331–3384.1. NADPH oxidase activity and its regulation
The results showed in this study extend our previous observations
on NADPH oxidase activation in human failing heart [10]. Although
other contribution in ROS generation cannot be ruled out, we
conﬁrmed a NADPH-dependent oxidase system as a major source of
O2− production in human failing hearts and shed light on the
molecular mechanisms underlying its increased activation. NADPH
oxidase is a multimeric enzyme that contains a core membrane-
bound ﬂavocytochrome comprising a catalytic Nox subunit and a
lower molecular weight p22phox subunit. Five distinct Nox isoforms
(Nox1–5) are expressed in a tissue-speciﬁc pattern, Nox2 and Nox4
being the main isoforms expressed in cardiac cells [26]. Nox2 oxidase
activation requires the association of the cytosolic regulatory units
(p67phox, Rac, p47phox and p40phox) with the ﬂavocytochrome [3]. At
variance with Nox2, Nox4 is constitutively active and has been
suggested to be regulated mainly at the transcriptional level [27].
NADPH oxidase activation in response to hypertrophic stimuli
(angiotensin II, epinephrine andmechanical overload) [28–31] occurs
through either increased expression or post-translational modiﬁca-
tions (by protein kinase c and/or Src kinase) and regulatory subunit
translocation (notably p47phox and /or Rac) [4,10,32–35]. Our
previous data showed that Nox2 protein expression did not differ
between NF and failing hearts, whereas both p47phox overexpression
and membrane translocation were increased with a higher p47phox
membrane/cytosol ratio in failing RV than LV [27]. To get further
insight into NADPH regulatory mechanisms, we analyzed the
expression of Nox4 in both failing ventricles. We did not observe
any increase in its expression, with Nox4 mRNA levels being
unchanged in failing ventricles with respect to NF ones. Overall,
these results suggest a prominent role of post-transcriptional
mechanisms in NADPH oxidase activation, in agreement with our
previous ﬁnding [10].
4.2. Antioxidant enzymes and their regulation
A major contribution of our results is the characterization of the
mutual relationship between oxidant and antioxidant activity in the
RV and LV fromhuman failing hearts. Despite amarked increase of CAT
and GPx activities, mRNA expression and protein levels were
unchanged for both enzymes. These ﬁndings support the hypothesis
that a dissociation might occur between mRNA/protein expression
and activity, suggesting that the adaptive response to increased
oxidative stress does not lead to increase transcription of these anti-
oxidant enzymes but may reﬂect a post-translational modiﬁcation.
NADPH oxidase ROS generation may mediate its effects through
different downstream signaling pathways including the activation of
redox-sensitive kinases [7–10]. In our previous investigations, we
demonstrated that in end-stage hearts and in cardiomyoblasts
exposed to simulated I/R conditions an increased NADPH oxidase
activitywas signiﬁcantly relatedwith enhanced lipid peroxidation and
activation of redox sensitive kinases [36].
In this study, we established a signiﬁcant correlation between
NADPH-dependent ROS production and antioxidant enzyme activity
in failing RV and LV. Furthermore, for both CAT and GPx activities, the
slope of the linear correlation appeared steeper in LV than in RV. On
the other hand, MDA levels, that some other authors related to
ventricular contractile dysfunction [37], were signiﬁcantly higher in
failing RV than LV. Taken together, these ﬁndings suggested that LV
might be more protected against oxidative stress.
Although the molecular mechanism underlying CAT (or GPx)
activation cannot be thoroughly investigated in this setting, recent
evidence in literature and our present results allow to infer a role for
protein Tyr-phosphorylation. In fact, Cao et al. [38,39] reported that in
vitro exposure to hydrogen peroxide activates the Abl family of
mammalian non-receptor tyrosine kinases, including c-Abl and Arg.Such activationwas associatedwith CAT andGPx phosphorylation and
their subsequent activity stimulation. In our samples, we found an
increase in CAT and GPx Tyr-phosphorylation in both failing ventricles
and, interestingly, the levels of these increases go hand-in-hand with
those of respective enzyme activities. To our knowledge, this is theﬁrst
evidence suggesting that such amechanismmaywork in human heart
disease. So, although speculative, for the limitation on ﬁnding a clear
evidence for a cause–effect relationship in end-stage hearts, it is
reasonable to hypothesize that increased NADPH oxidase ROS
production, as it activated redox sensitive kinases may activate c-Abl
and Arg kinases with the subsequent stimulation of the CAT and GPx
catalytic activities, a mechanism that may contribute to normalize the
level of oxidative stress.
At variance with CAT and GPx, and in line with previous study [23],
protein expression and enzymatic activity for Mn-SOD were un-
changed in failing ventricles, suggesting that this mitochondrial
enzyme may be not involved in the adaptive response to NADPH-
dependent oxidative stress in human heart failure. The observation of
an upregulation of Mn-SOD gene only in the right ventricle is
intriguing, and may reﬂect “site-related” mitochondrial differences,
that deserve additional investigation.
4.3. Conclusions and limitations
A mechanicistic interpretation of our results is prevented by the
usage of human samples from end-stage failing hearts; thus, the
contribution of post-translational modiﬁcations, in particular Tyr
phosphorylation, to the adaptive antioxidant response in human heart
disease remains to be established.
Overall, our ﬁndings show that the molecular and biochemical
mechanisms for cardiac failure although qualitatively similar, may be
quantitatively different in the right and left ventricle and suggest that
RV might be more vulnerable than LV against oxidative stress. In this
perspective, as recently pointed out [15], our study is in keeping with
a potential contribution of RV alterations to the progression toward
overt heart failure, and the expectation that gathering information on
RVmaladaptationmay translate into better treatment and prevention.
Acknowledgments
The ﬁnancial support of Ministero dell'Istruzione, dell'Università e
della Ricerca (M.I.U.R) and of Ente Cassa di Risparmio di Firenze is
gratefully acknowledged.
References
[1] J.A. Byrne, D.J. Grieve, A.C. Cave, A.M. Shah, Oxidative stress and heart failure, Arch.
Mal. Coeur Vaiss. 96 (2003) 214–221.
[2] F.J. Giordano, Oxygen, oxidative stress, hypoxia, and heart failure, J. Clin. Invest.
115 (2005) 500–508.
[3] C. Heymes, J.K. Bendall, P. Ratajczak, A.C. Cave, J.L. Samuel, G. Hasenfuss, A.M.
Shah, Increased myocardial NADPH oxidase activity in human heart failure, J. Am.
Coll. Cardiol. 41 (2003) 2164–2171.
[4] J.M. Li, N.P. Gall, D.J. Grieve, M. Chen, A.M. Shah, Activation of NADPH oxidase
during progression of cardiac hypertrophy to failure, Hypertension 40 (2002)
477–484.
[5] S. Dieterich, U. Bieligk, K. Beulich, G. Hasenfuss, J. Prestle, Gene expression of
antioxidative enzymes in the human heart, Circulation 101 (2000) 33–39.
[6] F.M. Hill, P.K. Singal, Antioxidant and oxidative stress changes during heart failure
subsequent to myocardial infarction in rats, Am. J. Pathol. 148 (1996) 291–300.
[7] A. Akki, M. Zhang, C. Murdoch, A. Brewer, A.M. Shah, NADPH oxidase signaling and
cardiac myocyte function, J. Mol. Cell. Cardiol. 47 (2009) 15–22.
[8] R. Dworakowski, N. Anilkumar, M. Zhang, A.M. Shah, Redox signalling involving
NADPH oxidase-derived reactive oxygen species, Biochem. Soc. Trans. (2006) 34.
[9] C. Murdoch, M. Zhang, A. Cave, A. Shah, NADPH oxidase-dependent redox
signalling in cardiac hypertrophy, remodelling and failure, Cardiovasc. Res. 71
(2006) 208–215.
[10] C. Nediani, E. Borchi, C. Giordano, S. Baruzzo, V. Ponziani, M. Sebastiani, P. Nassi, A.
Mugelli, G. d'Amati, E. Cerbai, NADPH Oxidase-dependent redox signaling in
human heart failure: relationship between the left and right ventricle, J. Mol. Cell.
Cardiol. 42 (2007) 826–834.
338 E. Borchi et al. / Biochimica et Biophysica Acta 1802 (2010) 331–338[11] A.T. Baumer, M. Flesch, X. Wang, Q. Shen, Z.G. Feuerstein, M. Bohm, Antioxidative
enzymes in human hearts with idiopatic dilated cardiomyopathy, J. Mol. Cell.
Cardiol. 32 (2000) 121–133.
[12] F. Sam, D. Kerstetter, D. Pimental, S. Mulukutla, A. Tabaee, M. Bristow, W. Colucci,
D. Sawyer, Increased reactive oxygen species production and functional
alterations in antioxidant enzymes in human failing myocardium, J. Card. Fail.
11 (2005) 473–480.
[13] A. Brieke, D. DeNofrio, Right ventricular dysfunction in chronic dilated
cardiomyopathy and heart failure, Coron. Artery Dis. 16 (2005) 5–11.
[14] F. Haddad, S.A. Hunt, D.N. Rosenthal, D.J. Murphy, Right ventricular function in
cardiovascular disease: Part I. anatomy, physiology, aging, and functional
assessment of the right ventricle, Circulation 117 (2008) 1436–1448.
[15] N. Voelkel, R. Quaife, L. Leinwand, R. Barst, M. McGoon, D. Meldrum, J. Dupuis, C.
Long, L. Rubin, F. Smart, Y. Suzuki, M. Gladwin, E. Denholm, D. Gail, National Heart,
Lung and Blood InstituteWorking Group on cellular andmolecular mechanisms of
right heart failure, right ventricular function and failure. Report of a National
Heart, Lung and Blood Institute Working Group on cellular and molecular
mechanisms of right heart failure, Circulation 114 (2006) 1883–1891.
[16] F.M. Hill, P.K. Singal, Right and left myocardial antioxidant responses during heart
failure subsequent to myocardial infarction, Circulation 96 (1997) 2414–2420.
[17] L. Liu, L. Marcocci, C. Wong, A. Park, Y. Suzuki, Serotonin-mediated protein
carbonylation in the right heart, Free Rad. Biol. Med. 45 (2008) 847–854.
[18] P. Modesti, S. Vanni, I. Bertolozzi, I. Cecioni, C. Lumachi, A. Perna, M. Boddi, G.
Gensini, Different growth factor activation in the right and left ventricles in
experimental volume overload, Hypertension 43 (2004) 101–108.
[19] N. Dang, V. Topkara, M. Mercando, J. Kay, K.H. Kruger, M.S. Aboodi, M.C. Oz, Y.
Naka, Right heart failure after left ventricular assist device implantation in
patients with chronic congestive heart failure, J. Heart Lung Transplant. 25 (2006)
1–6.
[20] A. Barbone, J. Holmes, P. Heerdt, A. The', Y. Naka, N. Joshi, M. Daines, A.R. Marks,
M.C. Oz, D. Burkhoff, Comparison of right and left ventricular responses to left
ventricular assist device support in patients with severe heart failure: a primary
role of mechanical unloading underlying reverse remodeling, Circulation 104
(2001) 670–675.
[21] S. Klotz, A. Barbone, S. Reiken, J. Holmes, Y. Naka, M.C. Oz, A.R. Marks, D. Burkhoff,
Left ventricular assist device support normalizes left and right ventricular beta-
adrenergic pathway properties, J. Am. Coll. Cardiol. 45 (2005) 668–676.
[22] S. Puwanant, K. Hamilton, C. Klodell, J. Hill, R. Schoﬁeld, T. Cleeton, D. Pauly, J.
Aranda, Tricuspid annular motion as a predictor of severe right ventricular failure
after left ventricular assist device implantation, J. Heart Lung Transplant. 27
(2008) 1102–1107.
[23] M. Sebastiani, C. Giordano, C. Nediani, C. Travaglini, E. Borchi, M. Zani, M. Feccia,
M. Mancini, V. Petrozza, A. Cossarizza, P. Gallo, R. Taylor, G. d'Amati, Induction of
mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardio-
myopathies, J. Am. Coll. Cardiol. 50 (2007) 1362–1369.[24] H. Aebi, Catalase in vitro, Methods Enzymol. 105 (1984) 121–126.
[25] S. Rhee, K. Yang, H. Woo, T. Chang, Controlled elimination of intracellular H2O2:
regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-
traslational modiﬁcation, Antioxid. Redox Signal. 7 (2005) 619–626.
[26] K. Bedard, K.H. Krause, The NOX family of ROS-generating NADPH oxidases:
physiology and pathophysiology, Physiol. Rev. 87 (2007) 245–313.
[27] J.D. Lambeth, NOX enzymes and the biology of reactive oxygen, Nat. Rev. Immunol
4 (2004) 181–189.
[28] C. Fiorillo, C. Nediani, V. Ponziani, L. Giannini, A. Celli, N. Nassi, L. Formigli, A.M.
Perna, P.A. Nassi, Cardiac volume overload rapidly induces oxidative stress-
mediated myocyte apoptosis and hypertrophy, Biochim. Biophys, Acta 1741
(2005) 173–182.
[29] J.M. Li, L.M. Fan, M.R. Christie, A.M. Shah, Acute tumor necrosis factor alpha
signaling via NADPH oxidase in microvascular endothelial cells: role of p47phox
phosphorylation and binding to TRAF4, Mol. Cell. Biol. 25 (2005) 2320–2330.
[30] J.M. Li, A.M. Shah, Mechanism of endothelial cell NADPH oxidase activation by
angiotensin II. Role of the p47 phox subunit, J. Biol. Chem. 278 (2003)
12094–12100.
[31] L. Xiao, D. Pimentel, J. Wang, K. Singh, W. Colucci, D. Sawyer, Role of reactive
oxygen species and NAD(P)H oxidase in alpha 1-adrenoceptor signaling in adult
rat cardiac myocytes, Am. J. Physiol. Cell. Physiol. 282 (2002) C926–C934.
[32] R. Gupte, V. Vijay, B. Marks, R. Levine, H. Sabbah, M. Wolin, F. Recchia, S. Gupte,
Upregulation of glucose-6-phosphate dehydrogenase and NAD(P)H oxidase
activity increases oxidative stress in failing human heart, J. Card. Fail. 13 (2007)
497–506.
[33] C. Maack, T. Kartes, H. Kilter, H. Schafers, G. Nickenig, M. Bohm, U. Laufs, Oxygen
free radical release in human failing myocardium is associated with increased
activity of Rac1-GTPase and represents a target for statin treatment, Circulation
108 (2003) 1567–1574.
[34] F. Qin, R. Patel, C. Yan,W. Liu, NADPH oxidase is involved in angiotensin II-induced
apoptosis in H9c2 cardiac muscle cells: effect of apocynin, Free Rad. Biol. Med. 40
(2006) 236–246.
[35] P. Seshiah, D.Weber, P. Rocic, L. Valppu, Y. Taniyama, K. Griendling, AngiotensinII ,
stimulation of NAD(P)H oxidase activity upstream mediators, Circ. Res. 91 (2002)
406–413.
[36] E. Borchi, M. Parri, L. Papucci, M. Becatti, N. Nassi, P. Nassi, C. Nediani, Role of
NADPH oxidase in H9c2 cardiac muscle cells exposed to simulated ischemia-
reperfusion, J. Cell. Mol. Med. (2008) Electronic publication ahead of print.
[37] D. Folden, A. Gupta, A. Sharma, S. Li, J. Saari, J. Ren, Malondialdehyde inhibits
cardiac contractile function in ventricular myocytes via a p38 mitogen-activated
protein kinase-dependent mechanism, Br. J. Pharmacol. 139 (2003) 1310–1316.
[38] C. Cao, Y. Leng, W. Huang, X. Liu, D. Kufe, Glutathione peroxidase 1 is regulated by
the c-Abl and Arg tyrosine kinases, J. Biol. Chem. 278 (2003) 39609–39614.
[39] C. Cao, Y. Leng, D. Kufe, Catalase activity is regulated by c-Abl and Arg in the
oxidative stress response, J. Biol. Chem. 278 (2003) 29667–29675.
